Literature DB >> 10502429

Ovarian carcinoma cell cultures are resistant to TGF-beta1-mediated growth inhibition despite expression of functional receptors.

S D Yamada1, R L Baldwin, B Y Karlan.   

Abstract

OBJECTIVE: The purpose of this study was to determine the response of ovarian carcinoma cells to TGF-beta1 and to examine components of the TGF-beta signaling pathway.
METHODS: Twenty-three primary ovarian cancer cell (CSOC) cultures established from solid ovarian carcinomas were treated with TGF-beta1 and assayed for growth response by MTT assay. Expression of TGF-beta receptor I (TbetaR-I) and receptor II (TbetaR-II), essential for effective signaling, was determined by Western analysis of CSOC cultures. TGF-beta1 ligand-induced phosphorylation of TbetaR-I was determined by immunoprecipitation of TbetaR-I followed by a protein kinase assay to assess TbetaR-I phosphorylation, an essential first step in TGF-beta signal transduction. Gelatin zymography performed on 5 CSOC cultures incubated with TGF-beta1 was used to determine TGF-beta's effect on matrix metalloproteinase production. Normal ovarian surface epithelial cells were used for comparison.
RESULTS: Eighteen of twenty-three (78%) CSOC cultures demonstrated no significant growth inhibition in response to TGF-beta1 treatment. All cell cultures expressed TbetaR-I and TbetaR-II and exhibited TbetaR-I phosphorylation following TGF-beta1 treatment. CSOC cultures produced significantly higher levels of matrix metalloproteinase-2 (MMP-2) than normal ovarian surface epithelial cells; however, the level of MMP-2 expression was not regulated by TGF-beta1.
CONCLUSION: These results indicate that TGF-beta1 resistance and higher levels of MMP-2 production may be inherent properties of the ovarian cancer phenotype. The initial steps in the TGF-beta signaling pathway, receptor expression, ligand binding, and TbetaR-I phosphorylation, appear to be functional in primary ovarian cancer cell cultures. Therefore, the mechanism of growth resistance is downstream of TbetaR-I phosphorylation. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10502429     DOI: 10.1006/gyno.1999.5535

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  18 in total

1.  MicroRNA-34c targets TGFB-induced factor homeobox 2, represses cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Yan Wang; Chun-Mei Wang; Zhen-Zhong Jiang; Xiao-Jian Yu; Chun-Guang Fan; Fei-Fei Xu; Qing Zhang; L I Li; Rui-Feng Li; Wen-Sheng Sun; Zhen-Hai Zhang; Yu-Gang Liu
Journal:  Oncol Lett       Date:  2015-08-27       Impact factor: 2.967

2.  Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.

Authors:  Pierre-Luc Mercier; Magdalena Bachvarova; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Karim Ghani; Bernard Têtu; Isabelle Bairati; Dimcho Bachvarov
Journal:  Mol Oncol       Date:  2011-07-26       Impact factor: 6.603

3.  TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment.

Authors:  Tsz-Lun Yeung; Cecilia S Leung; Kwong-Kwok Wong; Goli Samimi; Melissa S Thompson; Jinsong Liu; Tarrik M Zaid; Sue Ghosh; Michael J Birrer; Samuel C Mok
Journal:  Cancer Res       Date:  2013-07-03       Impact factor: 12.701

4.  Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer.

Authors:  Kun-Tu Yeh; Tze-Ho Chen; Hui-Wen Yang; Jian-Liang Chou; Lin-Yu Chen; Chia-Ming Yeh; Yu-Hsin Chen; Ru-Inn Lin; Her-Young Su; Gary C W Chen; Daniel E Deatherage; Yi-Wen Huang; Pearlly S Yan; Huey-Jen Lin; Kenneth P Nephew; Tim H-M Huang; Hung-Cheng Lai; Michael W Y Chan
Journal:  Epigenetics       Date:  2011-06-01       Impact factor: 4.528

Review 5.  Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis.

Authors:  Tsz-Lun Yeung; Cecilia S Leung; Kay-Pong Yip; Chi Lam Au Yeung; Stephen T C Wong; Samuel C Mok
Journal:  Am J Physiol Cell Physiol       Date:  2015-07-29       Impact factor: 4.249

6.  Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.

Authors:  Jian-Liang Chou; Her-Young Su; Lin-Yu Chen; Yu-Ping Liao; Corinna Hartman-Frey; Yi-Hui Lai; Hui-Wen Yang; Daniel E Deatherage; Chieh-Ti Kuo; Yi-Wen Huang; Pearlly S Yan; Shu-Huei Hsiao; Chien-Kuo Tai; Huey-Jen L Lin; Ramana V Davuluri; Tai-Kuang Chao; Kenneth P Nephew; Tim H-M Huang; Hung-Cheng Lai; Michael W-Y Chan
Journal:  Lab Invest       Date:  2010-01-11       Impact factor: 5.662

7.  Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer.

Authors:  Michael Wy Chan; Yi-Wen Huang; Corinna Hartman-Frey; Chieh-Ti Kuo; Daniel Deatherage; Huaxia Qin; Alfred Sl Cheng; Pearlly S Yan; Ramana V Davuluri; Tim H-M Huang; Kenneth P Nephew; Huey-Jen L Lin
Journal:  Neoplasia       Date:  2008-09       Impact factor: 5.715

8.  Changes in expression, and/or mutations in TGF-beta receptors (TGF-beta RI and TGF-beta RII) and Smad 4 in human ovarian tumors.

Authors:  Marie Lue Antony; Rema Nair; Paul Sebastian; Devarajan Karunagaran
Journal:  J Cancer Res Clin Oncol       Date:  2010-03       Impact factor: 4.553

9.  Lewis Y regulates signaling molecules of the transforming growth factor β pathway in ovarian carcinoma-derived RMG-I cells.

Authors:  Fei-Fei Li; Juan-Juan Liu; Da-Wo Liu; Bei Lin; Ying-Ying Hao; Jian-Ping Cong; Lian-Cheng Zhu; Song Gao; Shu-Lan Zhang; Masao Iwamori
Journal:  Int J Oncol       Date:  2011-12-13       Impact factor: 5.650

10.  An integrative ChIP-chip and gene expression profiling to model SMAD regulatory modules.

Authors:  Huaxia Qin; Michael W Y Chan; Sandya Liyanarachchi; Curtis Balch; Dustin Potter; Irene J Souriraj; Alfred S L Cheng; Francisco J Agosto-Perez; Elena V Nikonova; Pearlly S Yan; Huey-Jen Lin; Kenneth P Nephew; Joel H Saltz; Louise C Showe; Tim H M Huang; Ramana V Davuluri
Journal:  BMC Syst Biol       Date:  2009-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.